Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 single-arm study of letermovir prophylaxis in adult Japanese kidney transplant recipients
jRCT2080224932Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of letermovir in cytomegalovirus disease (CMV), sponsored by Merck & Co. Primary endpoints: Safety and Efficacy: CMV disease through Week 28 post-transplant. Started Oct 2019; status: completed.
02
Drugs
letermovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on jRCT2080224932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224932.